AAAleksandr A. Abramov

Aleksandr A. Abramov

*This is an algorithmically generated author record based on publicly available information.

Aleksandr A. Abramov has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    LncRNAs in Cancer Development

    by Alisa Petkevich, Aleksandr Abramov, Vadim Pospelov

    The goal of this chapter is to make an overview of the identified changes in lncRNAs expression levels accompanying cancer development. In general, the statistics allows us to establish a fact of association between the phenomenon and the process, but not to discover underlying mechanisms. In the context of the discussed topic, the phenomenon and the process are changes in lncRNA expression levels and cancer development. However, the underlying mechanisms, allowing such changes as in lncRNAs expression levels to have an impact on the cancer development, mostly remain uncertain and not clear. The first part of the chapter aims to shortly highlight the possible mechanisms of lncRNAs` impacts on the main processes of cancer development, like EMT, cancer cell progression, invasion, and metastasis. The second part examines in more detail the role of lncRNAs in some of the main nosology of oncological diseases: The participation of lncRNAs in the formation and development of breast cancer is considered, the main aspects of the importance of lncRNAs in lung cancer are presented, and studies on the participation of lncRNAs in the formation of colorectal cancer are described.


  • Open Access

    Pediatric Encephalopathy: Clinical, Biochemical and Cellular Insights into the Role of Gln52 of GNAO1 and GNAI1 for the Dominant Disease

    by Gonzalo P. Solis, Tatyana V. Kozhanova, Alexey Koval, Svetlana S. Zhilina, Tatyana I. Mescheryakova, Aleksandr A. Abramov, Evgeny V. Ishmuratov, Ekaterina S. Bolshakova, Karina V. Osipova, Sergey O. Ayvazyan, et al.

    Heterotrimeric G proteins are immediate transducers of G protein-coupled receptors—the biggest receptor family in metazoans—and play innumerate functions in health and disease. A set of de novo point mutations in GNAO1 and GNAI1, the genes encoding the α-subunits (Gαo and Gαi1, respectively) of the heterotrimeric G proteins, have been described to cause pediatric encephalopathies represented by epileptic seizures, movement disorders, developmental delay, intellectual disability, and signs of neurodegeneration. Among such mutations, the Gln52Pro substitutions have been previously identified in GNAO1 and GNAI1. Here, we describe the case of an infant with another mutation in the same site, Gln52Arg. The patient manifested epileptic and movement disorders and a developmental delay, at the onset of 1.5 weeks after birth. We have analyzed biochemical and cellular properties of the three types of dominant pathogenic mutants in the Gln52 position described so far: Gαo[Gln52Pro], Gαi1[Gln52Pro], and the novel Gαo[Gln52Arg]. At the biochemical level, the three mutant proteins are deficient in binding and hydrolyzing GTP, which is the fundamental function of the healthy G proteins. At the cellular level, the mutants are defective in the interaction with partner proteins recognizing either the GDP-loaded or the GTP-loaded forms of Gαo. Further, of the two intracellular sites of Gαo localization, plasma membrane and Golgi, the former is strongly reduced for the mutant proteins. We conclude that the point mutations at Gln52 inactivate the Gαo and Gαi1 proteins leading to aberrant intracellular localization and partner protein interactions. These features likely lie at the core of the molecular etiology of pediatric encephalopathies associated with the codon 52 mutations in GNAO1/GNAI1.